Ogo I Egbuna MD MMSc, FASN (He/Him)
Kidney & Pancreas Transplantation
Vice President, Clinical Development
Join to View Full Profile
50 Fan Pier BlvdBoston, MA 02210
Phone+1 617-692-0887
Dr. Egbuna is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Therapeutics development
Education & Training
Harvard-MIT School of Health Science and TechnologyMMSC, Clinical Investigation , 2006 - 2008- Brigham and Women’s HospitalPost Doctorate, Endocrinology, 2005 - 2008
Beth Israel Deaconess Medical Center/Harvard Medical SchoolFellowship, Transplant Nephrology, 2005 - 2006
University of Rochester Medical CenterFellowship, Nephrology, 2003 - 2005
Icahn School of Medicine at Mount Sinai/NYC Health and Hospitals (Elmhurst)Residency, Internal Medicine, 2000 - 2003
University of Nigeria Faculty of MedicineClass of 1998
Certifications & Licensure
CA State Medical License 2009 - 2017
Wharton Executive EducationCorporate Governnce
Awards, Honors, & Recognition
- K08 Investigators Award NIH, 2006-2008
- Fellow (ASNF) American Society of Nephrology
Clinical Trials
- A Randomized Trial to Reduce the Disparity in Live Donor Kidney Transplantation Start of enrollment: 2007 Aug 01
Publications & Presentations
PubMed
- 2 citationsSafety and Tolerability of the APOL1 Inhibitor, Inaxaplin, following Single- and Multiple-Ascending Doses in Healthy Adults.Ogo Egbuna, Vincent Audard, George Manos, Simon Tian, Fanuel Hagos
Glomerular Diseases. 2024-03-14 - 55 citationsInaxaplin for Proteinuric Kidney Disease in Persons with TwoVariants.Ogo Egbuna, Brandon Zimmerman, George Manos, Anne Fortier, Madalina C Chirieac
The New England Journal of Medicine. 2023-03-16 - Pharmacokinetic/pharmacodynamic and safety study of a single dose of evolocumab 140 mg in healthy Chinese subjects.Hong Lu, Zhigang Yu, Cheng-Pang Hsu, Brian Tomlinson, Andrea O.Y. Luk
International Journal of Clinical Pharmacology and Therapeutics. 2020-10-01
Press Mentions
Molecular Pathology Selected AbstractsJanuary 21st, 2024- Anatomic Pathology Selected AbstractsJanuary 23rd, 2024
Grant Support
- Human Uremic Persistent Hyperparathyroidism: Functional And Molecular AspectsNational Institute Of Diabetes And Digestive And Kidney Diseases2006–2008
Committees
- Member, Board of Directors, ASN-US FDA Kidney Health Initiative 2024 - Present
Professional Memberships
- Fellow
- Member
Industry Relationships
- Board Member, ASN-FDA Kidney Health InitiativeTo catalyze innovation and the development of safe and effective patient-centered therapies for people with kidney diseases.2024 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
